• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rubius Therapeutics Announces Strategic Update

    9/13/22 7:00:00 AM ET
    $RUBY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RUBY alert in real time by email

    Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform

    Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023

    Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid Tumors

    Investor Teleconference and Webcast Scheduled Today at 7:30 a.m. EDT

    CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to restructure the Company and align resources to advance its next generation red blood cell-based cell conjugation platform.

    "With more than 80 patients dosed across three clinical trials to date, Rubius Therapeutics has demonstrated that engineered red blood cells can be manufactured at scale, safely administered and activate a patient's immune system, resulting in clinical benefit in certain cancer patients, including evidence of tumor shrinkage and prolonged stable disease in PD-(L)-1 refractory solid tumors," said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics. "Based on these early findings, we firmly believe in the potential of Red Cell Therapeutics for the treatment of cancer and autoimmunity. Following careful review of recent technical progress in an alternative format for making Red Cell Therapeutics, we believe that this process has the potential for substantive improvements over our existing platform, and, therefore, continued investment in our two current clinical candidates is no longer justified. Instead, we plan to focus on advancing a next generation red blood cell platform that utilizes cell conjugation to potentially improve upon the existing benefits of the RED PLATFORM, with the potential for greater efficacy and enhanced versatility, while maintaining our favorable tolerability profile. As a result, we have decided to discontinue our ongoing clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors and restructure the organization to support advancing drug candidates based on the next generation platform. I would like to express my sincere gratitude to the patients who participated in our clinical trials, the investigators who partnered with us in this endeavor and our employees for their immense dedication and contributions that have brought us to where we are today."

    Next Generation Red Blood Cell-Based Conjugation Platform Overview

    The new platform is expected to improve upon the existing benefits of the RED PLATFORM, with the potential for greater efficacy and enhanced versatility, while maintaining a favorable tolerability profile, and reduce the complexity and cost of generating cells by leveraging chemical conjugation to produce Red Cell Therapeutics. Cell conjugation creates a covalent link between the cell surface and the molecule of interest. This approach is intended to:

    • deliver a higher effective dose by enabling a longer circulation time and/or administering a higher cell dose;
    • be more versatile, enabling the conjugation of different payloads, immunomodulatory agents, small molecules and proteins on the cell for enhanced potency; and
    • reduce the cost of goods manufacturing by utilizing blood-banked RBCs versus biologically engineering and differentiating early progenitor cells into reticulocytes that express proteins

    These attributes are expected to result in greater efficacy, a similar safety profile given the restricted biodistribution of RBCs to the spleen and vasculature and a significant reduction in overall cost structure.

    Business & Strategy Update

    To enable continued investment in the new platform, the Company is restructuring its business and implementing a series of cost-saving measures, which extends the Company's cash runway until the end of 2023. These measures include:

    • Implementing a 75% reduction in force, primarily focused on clinical development, manufacturing and general and administrative;
    • Discontinuing its ongoing Phase 1 clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors; and
    • Exploring the sale of its manufacturing facility in Smithfield, Rhode Island
      • Patients still on trial will continue to be dosed until disease progression or discontinuation (n=6)

    The Company will maintain its robust technical development and preclinical oncology and autoimmunity research capabilities to advance the new platform and related preclinical programs.

    Overview of Current Clinical Programs

    Phase 1 Clinical Trial of Monotherapy RTX-240

    As of September 12, 2022, 36 patients have been dosed in the monotherapy arm of the Phase 1/2 clinical trial of RTX-240 in advanced solid tumors. One patient with renal cell carcinoma remains on study with stable disease for more than one year after developing progressive disease on prior treatment with nivolumab. This ongoing patient was dose-escalated from the 3e10 x 3 + 1e10 Q3W dose level (n=6) to the 5e10 Q3W dose level after Cycle 12. Seven patients were dosed at 5e10 Q3W with one anal cancer patient experiencing stable disease for 5 months before disease progression. RTX-240 continued to be well tolerated with no treatment-related Grade 3/4 adverse events (AEs) and no dose-limiting toxicities.

    Phase 1 Clinical Trial of RTX-240 + Pembrolizumab in Advanced Solid Tumors

    Fourteen patients were dosed in the "all comers" dose-escalation portion of the Phase 1 clinical trial evaluating RTX-240 in combination with pembrolizumab in advanced solid tumors. Four patients had stable disease of greater than 12 weeks with one colorectal cancer patient remaining on study with stable disease of greater than 4 months. Two additional patients have been dosed in the non-clear cell RCC (nccRCC) and non-small cell lung cancer (NSCLC) expansion cohorts. Both patients remain on treatment with one nccRCC patient with stable disease greater than 12 weeks and one NSCLC patient who is not yet evaluable for response. The combination of RTX-240 with pembrolizumab continued to be well tolerated with no treatment or investigator-identified immune-related Grade 3/4 AEs and no dose-limiting toxicities.

    Phase 1 Clinical Trial of RTX-224 in Select Advanced Solid Tumors

    Seven patients have been dosed across two dose cohorts in the Phase 1 clinical trial evaluating RTX-224 in select advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer. One patient dosed at the 5e8 Q3W dose level with melanoma remains on study and is not yet evaluable for response. There have been no treatment-related Grade 3/4 AEs and no dose-limiting toxicities.

    Investor Teleconference & Webcast

    An audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website and can be directly accessed here. An archived webcast will be accessible for 90 days after the event.

    About Rubius Therapeutics

    Rubius Therapeutics is a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases. The Company was named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2022 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding beliefs about and expectation for the restructuring plan described in this release, including associated costs, cost savings and timing, as well as our beliefs about the next generation red blood cell platform, including that it will potentially improve upon the existing benefits of the RED PLATFORM, and its potential for greater efficacy and enhanced versatility. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this release, including, without limitation, risks related to the substantial doubt about our ability to continue as a going concern given that we currently do not have adequate financial resources to fund our forecasted operating costs for at least 12 months; our ability to execute on and realize the expected benefits of the restructuring plan described in this release; the amount of debt we have outstanding and the lender's rights under our loan facility, including the lender's ability to accelerate amounts outstanding under the loan facility, or exert control over our cash accounts in connection with certain events of default, including a material adverse change in our business; our ability to pursue and secure financing to fund our operations; our ability to maintain our listing on the Nasdaq Stock Market, particularly in light of our recently disclosed deficiencies; those risks and uncertainties related to the development of the our Red Cell Therapeutic product candidates and their therapeutic potential; risks related to our ability to execute on our plans and expectations and our analyses of clinical and preclinical data; and other risks identified in our filings with the U.S. Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter-ended June 30, 2022 and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. 

    Investor and Media Contact

    Lori Murray, Chief Corporate Affairs Officer

    [email protected]



    Primary Logo

    Get the next $RUBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RUBY

    DatePrice TargetRatingAnalyst
    9/13/2022Buy → Neutral
    Guggenheim
    2/25/2022$14.00 → $5.00Market Perform
    SVB Leerink
    11/9/2021$20.00 → $14.00Market Perform
    SVB Leerink
    10/19/2021$25.00 → $22.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $RUBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

      Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of

      11/2/22 4:01:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

      Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform.  www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo

      10/17/22 9:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cellarity Announces Close of $121 Million Series C Financing

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. Ltd. and Hanwha Impact Partners. The proceeds of the financing will be used to grow Cellarity's talent base, strengthen its platform, and advance its pipeline toward the clinic. "We welcome our new investors and appreciate the continued support of our current investors," said Fabrice Chouraqui, PharmD, CEO of Cellarit

      10/4/22 7:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RUBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rubius Therapeutics downgraded by Guggenheim

      Guggenheim downgraded Rubius Therapeutics from Buy to Neutral

      9/13/22 10:44:26 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

      SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $5.00 from $14.00 previously

      2/25/22 10:14:06 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

      SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $14.00 from $20.00 previously

      11/9/21 3:52:26 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Leadership Updates

    Live Leadership Updates

    See more
    • Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

      Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of

      11/2/22 4:01:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

      Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform.  www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo

      10/17/22 9:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

      BOSTON, July 19, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose "Pepe" Carmona to its Board of Directors. Mr. Carmona brings over 20 years of leadership experience in the biopharmaceutical industry across a range of roles and therapeutic areas. "We are thrilled to welcome Pepe to our Board of Directors," said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Thera

      7/19/22 7:00:00 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Appelhans Dannielle sold $1,323 worth of shares (10,385 units at $0.13), closing all direct ownership in the company

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/27/23 6:08:34 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Cagnoni Pablo J sold $2,112 worth of shares (8,448 units at $0.25), decreasing direct ownership by 11% to 66,082 units to cover withholding tax

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/1/23 9:41:05 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Appelhans Dannielle converted options into 7,500 shares and sold $970 worth of shares (3,878 units at $0.25), increasing direct ownership by 54% to 10,385 units to satisfy withholding tax

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/1/23 9:40:03 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Financials

    Live finance-specific insights

    See more
    • Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

      CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeuti

      7/26/22 8:00:00 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics to Announce First Quarter 2022 Financial Results

      CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results on Tuesday, May 10, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™.

      4/26/22 8:00:00 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

      Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or Dose-Limiting Toxicities as of the Cutoff Date Expanding Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer and Renal Cell Carcinoma Management to Host Conference Call Today at 1:15 p.m. EDT to Discuss Clinical Data and Clinical Development Next Steps for RTX-240 CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create

      4/8/22 1:00:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    SEC Filings

    See more
    • SEC Form 15-12G filed by Rubius Therapeutics Inc.

      15-12G - Rubius Therapeutics, Inc. (0001709401) (Filer)

      4/10/23 4:17:29 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Rubius Therapeutics, Inc. (0001709401) (Filer)

      4/6/23 5:11:23 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 25 filed by Rubius Therapeutics Inc.

      25 - Rubius Therapeutics, Inc. (0001709401) (Filer)

      3/28/23 4:23:38 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

      SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)

      4/10/23 9:37:13 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

      SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)

      3/3/23 11:28:09 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

      SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)

      2/14/23 1:00:53 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care